Extend the power of HPV testing

The BD Onclarity™ HPV Assay provides enhanced high-risk HPV genotyping results beyond 16 and 18, to support risk stratification and enhanced patient management.
Advancing HPV testing.
Enhancing patient management.

✔ Prepare for the changes in HPV genotype prevalence
Vaccination rates and the incidence of cervical adenocarcinoma are both on the rise, making HPV genotype testing an important tool to help stratify risk and enhance patient management.
- Genotypes 16 and 18 account for 70% of invasive cancer worldwide, but the prevalence of these genotypes is declining as vaccination rates increase1-5
- HPV high-risk genotypes 16, 18 and 45 account for 94% of cervical adenocarcinomas6

✔ Clarify patient risk with enhanced genotype detection
The BD Onclarity™ HPV Assay has been extensively tested in a clinical trial among over 33,000 women representing different ages, ethnicities and vaccinated and unvaccinated populations.7
The assay detects 14 high-risk genotypes and is the only FDA-approved HPV assay to individually report genotype 45.8

- Individual genotype reporting of 3 HR HPV types:
  
<table>
<thead>
<tr>
<th>16</th>
<th>18</th>
<th>45</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

- Individually (31, 51, 52) or concurrently (33/58, 35/39/68, 56/59/66) detects remaining HR HPV genotypes:
  
<table>
<thead>
<tr>
<th>31</th>
<th>51</th>
<th>52</th>
<th>33</th>
<th>35</th>
<th>39</th>
<th>68</th>
<th>56</th>
<th>59</th>
<th>66</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
  | Positive or Negative Pooled Result

- Genotype 45 causes 12% of cervical adenocarcinomas, and may be just as high-risk as genotype 186
- Patients who test positive for genotype 45 may need to be stratified into a higher risk level

✔ Adapt to evolving screening guidelines
The BD Onclarity™ HPV Assay is FDA approved for the paradigms below and offers the flexibility you need for changing screening guidelines.

- HPV Primary Screening
- Co-testing
- Cytology Primary + ASCUS Reflex

Patient management guidance may also evolve to include genotypes beyond 16 and 18. Be ready with the assay’s extended genotyping capabilities.

✔ Advance HPV testing accuracy
- Reduced risk of false-positive results due to lack of cross-reactivity with low-risk HPV types8
- Designed to minimize false-negative results by including an internal cellular control, ensuring that a sample is present

✔ Make more informed decisions
- Enables you to stratify patients according to risk7
- Allows you to monitor high-risk HPV genotypes and to potentially reduce unnecessary colposcopies

Enhance patient management with the BD Onclarity™ HPV Assay.


BD, 7 Loveton Circle, Sparks, MD 21152-0999 USA
Tel: 1.800.638.8663

bd.com

BD, the BD Logo and Onclarity are trademarks of Becton, Dickinson and Company or its affiliates. © 2019 BD. All rights reserved. 223531-US. October 2019